Canaccord Genuity Maintains a 'Hold' on Perrigo (PRGO); Consumer is Key to Upside in Stock Now
PRGO Hot Sheet
Rating Summary:8 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity maintains a 'Hold' on Perrigo Co. (NASDAQ: PRGO) price target of $105.00.
Analyst, Randall Stanicky, said, "PRGO put up a solid fiscal Q2 result off the back of another strong Generic Rx quarter and against a well-advertised weak cough-and-cold season. We exit the quarter more comfortable with the near-term outlook and what will likely be viewed as less risk to numbers from here. We did hear some concern today around (1) valuation in the context of greater Rx contribution (lower comp value) and (2) confidence in Consumer Health outlook given what is perhaps some unexpected competitive benefit. While fair, though not new, Perrigo is also benefiting from its diversified footprint with a better F2H launch outlook ahead. Bottom line, we think upside in Consumer Health is key to the stock from here, which is where our focus lies; remain HOLD for now."
For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.
Shares of Perrigo Co. closed at $95.26 yesterday, with a 52 week range of $70.94-$104.70.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Randall Stanicky, said, "PRGO put up a solid fiscal Q2 result off the back of another strong Generic Rx quarter and against a well-advertised weak cough-and-cold season. We exit the quarter more comfortable with the near-term outlook and what will likely be viewed as less risk to numbers from here. We did hear some concern today around (1) valuation in the context of greater Rx contribution (lower comp value) and (2) confidence in Consumer Health outlook given what is perhaps some unexpected competitive benefit. While fair, though not new, Perrigo is also benefiting from its diversified footprint with a better F2H launch outlook ahead. Bottom line, we think upside in Consumer Health is key to the stock from here, which is where our focus lies; remain HOLD for now."
For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.
Shares of Perrigo Co. closed at $95.26 yesterday, with a 52 week range of $70.94-$104.70.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
- Perrigo (PRGO) Gets FDA Approval for Generic Gynazole 1
- Nomura Securities Maintains a 'Buy' on Lowe's (LOW); Review of Q1
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
